By Fineline Cube 
Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today that its subsidiary Luzhou Buchang will enter into an exclusive supply arrangement with Helios Pharmaceutical Company Limited of Vietnam and ZaoAn International Trading Co., Ltd.. The agreement designates Helios as the sole distributor and ZaoAn International as the intermediary for the product Efparepoetin alfa Injection throughout Vietnam.
Key Agreement Elements
- Exclusive Distribution – Helios will manage registration, clinical trial coordination, marketing, and sales of Efparepoetin alfa in Vietnam.
- Intermediary Role – ZaoAn International will handle regulatory filings, logistics, and trade facilitation.
- Scope of the Product – The recombinant fusion protein (human EPO + human IgG2 Fc) treats anemia in adult dialysis patients with chronic kidney disease (CKD).
Market Significance
- First‑In‑Class – Efparepoetin alfa is a Class 1 biologic, and it is the only product of its kind approved for CKD‑related anemia in China.
- Regulatory Momentum – The product has already submitted a marketing authorization application in China, positioning it for a swift launch in Vietnam once local approvals are secured.
- Strategic Expansion – The partnership opens a new growth channel for Shandong Buchang in Southeast Asia, leveraging Helios’s distribution network and ZaoAn International’s trade expertise.
Forward‑Looking Statements
Statements herein that are not historically material facts are forward‑looking and are based on current expectations. These involve risks and uncertainties that may cause actual results to differ materially.-Fineline Info & Tech